Best, Jennie H.
Sadeghi, Mitra
Sun, Xiaowu
Seetasith, Arpamas
Albensi, Lisa
Joshi, Seema
Zervos, Marcus J.
Funding for this research was provided by:
Genentech
Article History
Received: 27 October 2023
Accepted: 2 February 2024
First Online: 14 March 2024
Declarations
:
: J.H. Best, M. Sedeghi, and A. Seetasith are employees of Genentech, Inc., and hold shares in F. Hoffmann-La Roche Ltd. L. Albensi was formerly an employee of CVS at the time of this analysis. X. Sun is an employee and shareholder of CVS. S. Joshi has no disclosures. M. Zervos has received funding from ContraFect (consultant), GSK (grant/research support), Johnson & Johnson (grant/research support), and Pfizer (grant/research support).
: The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor, and followed generally accepted research practices described in Good Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research and Good Pharmacoepidemiology Practice guidelines. Sponsor approval and continuing review was obtained through a central institutional review board (Sterling IRB), which evaluated this study and safeguarded the rights and welfare of participants. All patients provided informed consent.